What we do
Developing bioequivalent formulations of high barrier to entry products with significant development, legal and regulatory challenges. We are focused on targeting high-value solid oral and alternative dosage form ANDAs that are difficult to develop and that bring sustainable profitability.
Developing differentiated products by applying our ElectroNanospray (ENS) platform to improve the performance of existing drug products with poor solubility, low bioavailability, high food effect, or variable PK.
Enable formulations for preclinical development. Nanocopoeia is a formulation and process resource for the pharmaceutical industry. Nanocopoeia works with drug development companies to create efficient and effective ways to enable formulations of challenging new chemical entities and/or leverage existing libraries of compounds with known solubility issues but potentially significant commercial value.
Improving drugs through nanoformulation of challenging APIs
Novel ENS platform
Uniform, small, amorphous particles
Speed to Market
Rapid process optimization
New intellectual property Lifecycle management